PhytoHealth Corporation (4108.TW)

TWD 16.15

(0.31%)

Revenue Summary of PhytoHealth Corporation

  • PhytoHealth Corporation's latest annual revenue in 2023 was 162.48 Million TWD , up 19.95% from previous year.
  • PhytoHealth Corporation's latest quarterly revenue in 2024 Q2 was 44.12 Million TWD , up 35.4% from previous quarter.
  • PhytoHealth Corporation reported a annual revenue of 135.46 Million TWD in annual revenue 2022, down -19.81% from previous year.
  • PhytoHealth Corporation reported a annual revenue of 168.93 Million TWD in annual revenue 2021, up 84.01% from previous year.
  • PhytoHealth Corporation reported a quarterly revenue of 44.12 Million TWD for 2024 Q2, up 35.4% from previous quarter.
  • PhytoHealth Corporation reported a quarterly revenue of 39.81 Million TWD for 2024 Q3, down -9.76% from previous quarter.

Annual Revenue Chart of PhytoHealth Corporation (2023 - 2009)

Historical Annual Revenue of PhytoHealth Corporation (2023 - 2009)

Year Revenue Revenue Growth
2023 162.48 Million TWD 19.95%
2022 135.46 Million TWD -19.81%
2021 168.93 Million TWD 84.01%
2020 91.81 Million TWD -3.85%
2019 95.48 Million TWD -11.16%
2018 107.48 Million TWD 99.06%
2017 53.99 Million TWD 115.8%
2016 25.02 Million TWD 19.27%
2015 20.97 Million TWD -76.88%
2014 90.73 Million TWD -37.42%
2013 144.98 Million TWD -18.41%
2012 177.71 Million TWD 14.58%
2011 155.09 Million TWD 43.73%
2010 107.9 Million TWD 8.78%
2009 99.19 Million TWD 0.0%

Peer Revenue Comparison of PhytoHealth Corporation

Name Revenue Revenue Difference
Grape King Bio Ltd 10.63 Billion TWD 98.472%
Standard Chem & Pharm CO., LTD. 6.23 Billion TWD 97.396%
Maywufa Company Ltd. 1.3 Billion TWD 87.508%
ScinoPharm Taiwan, Ltd. 3.18 Billion TWD 94.9%
Lotus Pharmaceutical Co., Ltd. 16.95 Billion TWD 99.042%
LIWANLI Innovation Co., Ltd. 38.88 Million TWD -317.849%
YungShin Global Holding Corporation 7.02 Billion TWD 97.688%
SCI Pharmtech, Inc. 1.2 Billion TWD 86.506%
Formosa Laboratories, Inc. 4.36 Billion TWD 96.274%
PharmaEssentia Corporation 5.1 Billion TWD 96.817%
Bora Pharmaceuticals Co., LTD. 14.2 Billion TWD 98.856%